EUR526,500 Nordic Agreement Expands Felix European Footprint

Key points

• EUR526,500 minimum contracted value across three years
• NOVIVITAE appointed exclusive commercialisation partner
• Agreement expands Felix footprint to nine European countries
• Nordic markets have high utilisation of assisted reproductive technology

Full summary

Memphasys Limited has entered into an exclusive commercialisation agreement with NOVIVITAE ApS for the sale and commercialisation of the Felix System across Denmark, Sweden, Norway, Finland, and Iceland. This agreement, which includes a EUR526,500 minimum contracted value over three years, expands Felix's European commercial footprint to nine countries. NOVIVITAE, a Denmark-based IVF and laboratory-technology distributor, will serve as the exclusive commercialisation partner across the Nordic territory, subject to minimum purchase and performance obligations. The Nordic countries, with approximately 55,000 ART treatment cycles in 2020, represent a significant opportunity for recurring revenue as clinics adopt the Felix System.

Guidance

EUR526,500 minimum contracted value over three years

Outlook

Memphasys plans to focus on supply, training, market development, and clinic engagement in the near term, with quarterly minimum purchase commitments starting after the three-month evaluation period.